Poolbeg Pharma a year of substantial progress

Poolbeg Pharma

Poolbeg Pharma Plc (LON:POLB, OTCQB: POLBF), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, has confirmed that the Company’s Annual Report and Accounts for the period ended 31 December 2022 and the notice of Annual General Meeting 2022 have been posted to shareholders.

The Notice of AGM and accompanying form of proxy are available to download from the Company’s website: https://www.poolbegpharma.com/investors/documents/  while the 2022 Annual Report and Accounts can be viewed and downloaded below.

The Annual General Meeting will be held at the offices of DAC Beachcroft LLP, 25 Walbrook, London EC4N 8AF, United Kingdom on 11 May 2023 at 12pm.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Poolbeg Pharma granted extension to PUSU Deadline

HOOKIPA Pharma and Poolbeg Pharma enter talks for a potential acquisition aimed at developing next-generation immunotherapies for critical medical needs.

Poolbeg Pharma update on potential combination with HOOKIPA

Poolbeg Pharma and HOOKIPA Pharma propose a new collaboration with Gilead Sciences set to invest up to $8.7495 million, pending further negotiations.

Poolbeg Pharma y HOOKIPA Pharma actualizan su recaudación de fondos con el apoyo de Gilead Sciences

Los Consejos de Poolbeg Pharma y HOOKIPA Pharma anuncian el respaldo de Gilead para una posible oferta y la actualización de su recaudación de fondos.

Poolbeg Pharma and HOOKIPA Pharma fundraise update with Gilead Sciences’ support

Poolbeg Pharma and HOOKIPA Pharma confirm Gilead Sciences' support for participation in a $30 million+ private placement fundraise amid potential merger talks.

HOOKIPA Pharma and Poolbeg discuss all-share acquisition

HOOKIPA Pharma and Poolbeg Pharma are exploring a potential all-share acquisition, aiming to create a powerful Nasdaq-listed biopharmaceutical entity.

Poolbeg Pharma plc presents POLB 001 pre-clinical study data at the 66th ASH meeting

Poolbeg Pharma unveils promising POLB 001 data at ASH Meeting, highlighting its potential as a CRS preventative therapy in cancer immunotherapies.

Search

Search